JP6648115B2 - 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体 - Google Patents

変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体 Download PDF

Info

Publication number
JP6648115B2
JP6648115B2 JP2017515059A JP2017515059A JP6648115B2 JP 6648115 B2 JP6648115 B2 JP 6648115B2 JP 2017515059 A JP2017515059 A JP 2017515059A JP 2017515059 A JP2017515059 A JP 2017515059A JP 6648115 B2 JP6648115 B2 JP 6648115B2
Authority
JP
Japan
Prior art keywords
oxo
chloro
methyl
amino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528487A (ja
JP2017528487A5 (cg-RX-API-DMAC10.html
Inventor
スーザン アシュウェル，
スーザン アシュウェル，
アン−マリエ キャンベル，
アン−マリエ キャンベル，
ジャスティン アンドリュー カラベラ，
ジャスティン アンドリュー カラベラ，
アール． ブルース ディボールド，
アール． ブルース ディボールド，
アンナ エリクソン，
アンナ エリクソン，
ゲイリー ガスタフソン，
ゲイリー ガスタフソン，
デイビッド アール． ジュニア ランシア，
デイビッド アール． ジュニア ランシア，
ジャン リン，
ジャン リン，
ウェイ ルー，
ウェイ ルー，
ツォングォ ワン，
ツォングォ ワン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forma Therapeutics Inc
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of JP2017528487A publication Critical patent/JP2017528487A/ja
Publication of JP2017528487A5 publication Critical patent/JP2017528487A5/ja
Application granted granted Critical
Publication of JP6648115B2 publication Critical patent/JP6648115B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2017515059A 2014-09-19 2015-09-18 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体 Active JP6648115B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462053006P 2014-09-19 2014-09-19
US62/053,006 2014-09-19
US201562128089P 2015-03-04 2015-03-04
US62/128,089 2015-03-04
US201562150812P 2015-04-21 2015-04-21
US62/150,812 2015-04-21
PCT/US2015/051055 WO2016044789A1 (en) 2014-09-19 2015-09-18 Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Publications (3)

Publication Number Publication Date
JP2017528487A JP2017528487A (ja) 2017-09-28
JP2017528487A5 JP2017528487A5 (cg-RX-API-DMAC10.html) 2019-10-10
JP6648115B2 true JP6648115B2 (ja) 2020-02-14

Family

ID=54291606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515059A Active JP6648115B2 (ja) 2014-09-19 2015-09-18 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体

Country Status (37)

Country Link
US (8) US9834539B2 (cg-RX-API-DMAC10.html)
EP (4) EP3194376B1 (cg-RX-API-DMAC10.html)
JP (1) JP6648115B2 (cg-RX-API-DMAC10.html)
KR (1) KR102209667B1 (cg-RX-API-DMAC10.html)
CN (3) CN117695280A (cg-RX-API-DMAC10.html)
AU (3) AU2015317329B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017005238B1 (cg-RX-API-DMAC10.html)
CA (1) CA2961817C (cg-RX-API-DMAC10.html)
CL (1) CL2017000658A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017003241A2 (cg-RX-API-DMAC10.html)
CY (2) CY1121149T1 (cg-RX-API-DMAC10.html)
DK (2) DK3447050T3 (cg-RX-API-DMAC10.html)
EA (1) EA034336B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP17022933A (cg-RX-API-DMAC10.html)
ES (3) ES2953347T3 (cg-RX-API-DMAC10.html)
FI (1) FI3733662T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20200666T1 (cg-RX-API-DMAC10.html)
HU (2) HUE062424T2 (cg-RX-API-DMAC10.html)
IL (3) IL292608B2 (cg-RX-API-DMAC10.html)
LT (2) LT3447050T (cg-RX-API-DMAC10.html)
MA (2) MA40481A (cg-RX-API-DMAC10.html)
ME (1) ME03776B (cg-RX-API-DMAC10.html)
MX (2) MX2017003404A (cg-RX-API-DMAC10.html)
MY (2) MY176250A (cg-RX-API-DMAC10.html)
NZ (1) NZ730373A (cg-RX-API-DMAC10.html)
PE (1) PE20171056A1 (cg-RX-API-DMAC10.html)
PH (1) PH12017500517B1 (cg-RX-API-DMAC10.html)
PL (3) PL3194376T3 (cg-RX-API-DMAC10.html)
PT (3) PT3733662T (cg-RX-API-DMAC10.html)
RS (2) RS60140B1 (cg-RX-API-DMAC10.html)
SA (1) SA517381129B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201702194SA (cg-RX-API-DMAC10.html)
SI (2) SI3194376T1 (cg-RX-API-DMAC10.html)
SM (2) SMT201900018T1 (cg-RX-API-DMAC10.html)
TW (1) TWI686390B (cg-RX-API-DMAC10.html)
WO (1) WO2016044789A1 (cg-RX-API-DMAC10.html)
ZA (3) ZA201702127B (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
CA2793835C (en) * 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
RS57843B1 (sr) 2014-02-06 2018-12-31 Heptares Therapeutics Ltd Biciklična aza jedinjenja kao agonisti muskarinskog receptora m1
MX373789B (es) 2014-09-19 2020-03-23 Forma Therapeutics Inc Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
ES2706888T3 (es) 2014-09-19 2019-04-01 Forma Therapeutics Inc Referencia cruzada a aplicaciones relacionadas
CN107001331A (zh) 2014-09-19 2017-08-01 拜耳制药股份公司 作为bub1抑制剂的苄基取代的吲唑
WO2016044781A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
ES2953347T3 (es) 2014-09-19 2023-11-10 Forma Therapeutics Inc Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante
CN107428690B (zh) * 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US11827616B2 (en) 2017-05-04 2023-11-28 Discovery Purchaser Corporation Heterocyclic compounds as pesticides
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
WO2020232381A1 (en) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
HUE061331T2 (hu) * 2018-05-16 2023-06-28 Forma Therapeutics Inc Mutáns IDH-1 gátlása
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
LT3720442T (lt) 2018-05-16 2023-04-25 Forma Therapeutics, Inc. Mutantinės idh-1 slopinimas
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) * 2019-11-20 2023-01-31 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112341389B (zh) * 2020-10-27 2022-07-29 浙江工业大学 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN112321571B (zh) * 2020-10-27 2022-06-03 浙江工业大学 2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
JP2005532368A (ja) 2002-06-12 2005-10-27 アボット・ラボラトリーズ メラニン濃縮ホルモン受容体の拮抗薬
WO2004043936A1 (ja) 2002-11-14 2004-05-27 Kyowa Hakko Kogyo Co., Ltd. Ｐｌｋ阻害剤
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
US7956060B2 (en) 2004-03-30 2011-06-07 Kyowa Hakko Kirin Co., Ltd. Pyrimidine derivative compound
WO2006054912A1 (fr) * 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
AU2007275816A1 (en) * 2006-07-17 2008-01-24 Merck Sharp & Dohme Corp. 1-hydroxy naphthyridine compounds as anti-HIV agents
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
CA2684968C (en) 2007-04-30 2015-07-07 Prometic Biosciences Inc. Compounds, compositions containing such compounds, and methods of treatment of cancer and autoimmune diseases using such compounds
EP2440050A4 (en) 2009-06-08 2013-04-03 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
ES2642109T3 (es) * 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
CN102558049B (zh) 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
GEP20166432B (en) 2011-09-27 2016-02-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
KR102097343B1 (ko) 2011-12-21 2020-04-07 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 RAL GTPases를 타겟으로 하는 항암용 화합물 및 이의 사용방법
RS57401B1 (sr) 2012-01-06 2018-09-28 Agios Pharmaceuticals Inc Terapeutski aktivna jedinjenja i postupci za njihovu upotrebu
CA2903176A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
JP6534675B2 (ja) 2014-02-11 2019-06-26 バイエル・ファルマ・アクティエンゲゼルシャフト ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
ES2706888T3 (es) 2014-09-19 2019-04-01 Forma Therapeutics Inc Referencia cruzada a aplicaciones relacionadas
WO2016044781A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
MX373789B (es) 2014-09-19 2020-03-23 Forma Therapeutics Inc Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
ES2953347T3 (es) * 2014-09-19 2023-11-10 Forma Therapeutics Inc Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante
CN107428690B (zh) 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
EP3328866B1 (en) 2015-07-27 2019-10-30 Eli Lilly and Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
KR20180114202A (ko) 2016-02-26 2018-10-17 아지오스 파마슈티컬스 아이엔씨. 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제
US10696665B2 (en) 2016-06-06 2020-06-30 Eli Lilly And Company Mutant IDH1 inhibitors
JP6987798B2 (ja) 2016-06-22 2022-01-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 癌の治療に変異体ｉｄｈ１阻害剤として有用なチアゾール誘導体
ES2941631T3 (es) 2016-12-16 2023-05-24 Lilly Co Eli Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes

Also Published As

Publication number Publication date
US20240150319A1 (en) 2024-05-09
US20170174658A1 (en) 2017-06-22
SMT201900018T1 (it) 2019-02-28
US20180312487A1 (en) 2018-11-01
AU2019283765B2 (en) 2021-05-13
PE20171056A1 (es) 2017-07-21
PT3447050T (pt) 2020-09-17
WO2016044789A1 (en) 2016-03-24
KR102209667B1 (ko) 2021-01-29
AU2019283765A1 (en) 2020-01-16
BR112017005238A2 (pt) 2017-12-19
AU2015317329A1 (en) 2017-04-27
SI3447050T1 (sl) 2020-08-31
CY1121149T1 (el) 2020-05-29
MY197533A (en) 2023-06-21
TWI686390B (zh) 2020-03-01
MX385512B (es) 2025-03-18
US20200223822A1 (en) 2020-07-16
US20230125739A1 (en) 2023-04-27
ZA201902446B (en) 2023-12-20
HUE041460T2 (hu) 2019-05-28
EP3194376A1 (en) 2017-07-26
LT3447050T (lt) 2020-05-11
US11498913B2 (en) 2022-11-15
US12275715B2 (en) 2025-04-15
IL251163A0 (en) 2017-04-30
IL292608B2 (en) 2024-10-01
JP2017528487A (ja) 2017-09-28
MA40481A (fr) 2017-07-26
PT3733662T (pt) 2023-08-18
MY176250A (en) 2020-07-24
DK3194376T3 (en) 2019-01-21
EP4257131A2 (en) 2023-10-11
PH12017500517B1 (en) 2022-08-03
CL2017000658A1 (es) 2017-12-22
LT3194376T (lt) 2019-02-25
HUE062424T2 (hu) 2023-11-28
MX2017003404A (es) 2017-07-28
MX2019013203A (es) 2020-01-20
PH12017500517A1 (en) 2017-08-07
RS60140B1 (sr) 2020-05-29
US20160083366A1 (en) 2016-03-24
PL3194376T3 (pl) 2019-05-31
IL282363B (en) 2022-06-01
SMT202000212T1 (it) 2020-05-08
ES2704897T3 (es) 2019-03-20
US20210078973A1 (en) 2021-03-18
HRP20200666T1 (hr) 2020-07-24
EP3194376B1 (en) 2018-10-24
ES2790640T3 (es) 2020-10-28
CY1122865T1 (el) 2021-05-05
EP3733662A1 (en) 2020-11-04
CA2961817C (en) 2024-03-12
AU2021215141B2 (en) 2023-10-19
MA53352A (fr) 2021-09-15
ECSP17022933A (es) 2017-08-31
KR20170063742A (ko) 2017-06-08
PL3733662T3 (pl) 2024-01-22
IL292608A (en) 2022-07-01
PT3194376T (pt) 2019-02-04
EP3733662B1 (en) 2023-06-07
IL292608B1 (en) 2024-06-01
US10889567B2 (en) 2021-01-12
TW201617335A (zh) 2016-05-16
CN111909130B (zh) 2023-10-31
CA2961817A1 (en) 2016-03-24
US20190263778A1 (en) 2019-08-29
SG11201702194SA (en) 2017-04-27
EP4257131A3 (en) 2024-01-10
NZ758641A (en) 2023-12-22
BR112017005238B1 (pt) 2023-01-17
IL282363A (en) 2021-06-30
ZA202304409B (en) 2024-08-28
IL251163B (en) 2021-05-31
ME03776B (me) 2021-04-20
NZ730373A (en) 2019-11-29
FI3733662T3 (fi) 2023-08-09
AU2021215141A1 (en) 2021-09-02
EA201790657A1 (ru) 2017-08-31
SI3194376T1 (sl) 2019-03-29
ES2953347T3 (es) 2023-11-10
CN111909130A (zh) 2020-11-10
CO2017003241A2 (es) 2017-09-20
US10414752B2 (en) 2019-09-17
US10550098B2 (en) 2020-02-04
DK3447050T3 (da) 2020-03-09
EA034336B1 (ru) 2020-01-29
PL3447050T3 (pl) 2020-07-27
US9834539B2 (en) 2017-12-05
ZA201702127B (en) 2019-06-26
EA201790657A8 (ru) 2018-02-28
CN107001328B (zh) 2020-06-05
EP3447050A1 (en) 2019-02-27
SA517381129B1 (ar) 2021-04-26
EP3447050B1 (en) 2020-02-19
CN107001328A (zh) 2017-08-01
CN117695280A (zh) 2024-03-15
AU2015317329B2 (en) 2019-10-31
RS58184B1 (sr) 2019-03-29

Similar Documents

Publication Publication Date Title
JP6648115B2 (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジン−２（１ｈ）−オンキノリノン誘導体
JP6751081B2 (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
JP6820836B2 (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのフェニルキノリノン誘導体
HK40102356A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40033589B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40033589A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40002980A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40002980B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK1241376A1 (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK1241376B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20190603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190606

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200115

R150 Certificate of patent or registration of utility model

Ref document number: 6648115

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250